T1	p 35 74	in people at high cardiovascular risk :
T2	p 117 139	people with diabetes ,
T3	p 218 242	to renal insufficiency .
T4	p 286 310	nondiabetic population .
T5	p 370 381	over 4.5 yr
T6	p 496 577	9297 participants , including 3577 with diabetes and 1956 with microalbuminuria .
T7	p 607 629	7674 participants with
T8	p 688 745	criteria were known vascular disease or diabetes plus one
T9	p 781 857	exclusion criteria included heart failure or known impaired left ventricular
T10	p 901 902	>
T11	p 931 936	> 2.3
T12	p 1155 1189	participants without diabetes ( OR
T13	p 1232 1263	participants with diabetes ( OR
T14	p 1412 1426	participants ;
T15	p 1469 1485	317 participants
T16	p 1634 1662	and with diabetes who are at
T17	p 1814 1850	nondiabetic and in diabetic people .
T18	i 462 473	ramipril 's
T19	i 485 492	placebo
T20	i 737 745	plus one
T21	i 1519 1527	Ramipril
T22	i 1849 1859	. Ramipril
T23	o 73 74	:
T24	o 197 217	clinical proteinuria
T25	o 355 369	of proteinuria
T26	o 389 401	HOPE ( Heart
T27	o 415 425	Prevention
T28	o 767 771	risk
T29	o 809 814	heart
T30	o 846 898	ventricular function , dipstick-positive proteinuria
T31	o 910 930	and serum creatinine
T32	o 969 985	microalbuminuria
T33	o 996 1027	subsequent clinical proteinuria
T34	o 1368 1394	new clinical proteinuria )
T35	o 1446 1462	microalbuminuria
T36	o 1496 1516	clinical proteinuria
T37	o 1540 1544	risk
T38	o 1553 1566	progression (
T39	o 1799 1810	proteinuria